In a welcome move, BioNTech ADR saw its Relative Strength Rating rise from 67 to 71 on Friday.
How To Invest In Stocks In Both Bull And Bear Markets
This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the top-performing stocks typically have an RS Rating of at least 80 as they launch their largest climbs. See if BioNTech ADR can continue to show renewed price strength and clear that threshold.
While it's not currently an ideal time to buy shares, see if the stock manages to form a base and break out.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -46% to 0%. Revenue rose from -25% to -2%.
The company earns the No. 229 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
